Tenax Therapeutics

Oral levosimendan for PH-HFpEF

TENX · Nasdaq · United States

Share price · TENX

$1.43-0.27 (-15.88%) 3M

close as of 2026-11-18 · 24h delayed · vol 1.5M (0.8x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when TENX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 10 Aug 2026-89.8%
  2. 27 Jul 2026+11.4%
  3. 2 Jul 2026+16.3%
  4. 1 Jul 2026-8.7%
  5. 30 Jun 2026+7.8%
  6. 24 Jun 2026-5.2%

    Nothing announced by TENX that day or the session before.

  7. 23 Jun 2026+11.3%

    Nothing announced by TENX that day or the session before.

  8. 10 Mar 2026+31.7%
  9. 15 Jan 2026-13.0%

    Nothing announced by TENX that day or the session before.

  10. 14 Jan 2026+21.4%

    Nothing announced by TENX that day or the session before.

Share of unusual movement by asset

For each asset, the share of TENX's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Levosimendan (Simdax)
events and moves
1146%
Other company news (earnings, financing, releases naming no asset)—16%
Sessions with no dated event—38%

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Levosimendan(Simdax)
Phase 3
Cardiac troponin C (calcium sensitizer)Small molecule
Heart FailurePulmonary Hypertension due to Left Heart Disease

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
June 2028 (1)
Levosimendan · SimdaxPhase 3Pulmonary Hypertension Associated With HFpEF
Est. primary completion 2028-06-30 · NCT07288398 · CT.gov ↗
What to watch
2029 (1)
March 2029 (1)
Levosimendan · SimdaxPhase 3Pulmonary Hypertension Associated With HFpEF
Est. primary completion 2029-03 · NCT07436689 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

10 August 2026Topline resultLevosimendanPhase 3 LEVEL topline: primary endpoint not met
Tenax Therapeutics · Source ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3—$12M$114M$17M-$12M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$13M$118M$18M-$14M operating cash flowreport ↗
2026-Q1$0$12M$119M$16M-$9.3M operating cash flowreport ↗
2025-Q3—$10M$99M$16M-$9.2M operating cash flowreport ↗
2025-Q2—$6.1M$105M$11M-$6.3M operating cash flowreport ↗
2025-Q1$0$5.7M$111M$10M-$7.0M operating cash flowreport ↗
2024-Q3—$3.1M$98M—-$3.1M operating cash flowreport ↗
2024-Q2—$2.3M$9.4M—-$3.0M operating cash flowreport ↗
2024-Q1—$2.7M$13M—-$5.2M operating cash flowreport ↗
2023-Q3—$1.1M$11M—-$2.1M operating cash flowreport ↗
2023-Q2—$0.2M$13M$1.1M-$0.9M operating cash flowreport ↗
2023-Q1—$0.3M$14M—-$1.7M operating cash flowreport ↗
2022-Q3—$1.5M$3.8M—-$3.3M operating cash flowreport ↗
2022-Q2—$1.5M$7.2M—-$3.4M operating cash flowreport ↗
2022-Q1—$1.2M$2.9M$2.7M-$2.9M operating cash flowreport ↗
2021-Q3—$1.2M$8.3M+ $0 short-term inv.—-$3.0M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$0$33M$98M$13M-$36M operating cash flowreport ↗

Tenax Therapeutics reported no revenue for 2025, with R&D expenses of $32.67M, up 157% YoY, and a net loss of $52.6M. Cash and cash equivalents stood at $97.57M as of December 31, 2025.

The company expects its cash to fund operations through 2027. Tenax achieved its randomization target of 230 patients in the Phase 3 LEVEL study, with topline data expected in the third quarter of 2026, and initiated the global Phase 3 LEVEL-2 trial as well as an open-label extension study. In December 2025, a prespecified blinded sample size re-estimation showed the LEVEL study was powered at well over 90% to detect a 25-meter change in six-minute walk distance, and in January 2026 the USPTO issued a Notice of Allowance for subcutaneous levosimendan formulations.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$0$13M$95M$4.4M-$15M operating cash flowreport ↗
2023-FY—$3.2M$9.8M—-$5.9M operating cash flowreport ↗
2022-FY—$5.4M$2.1M$2.8M-$12M operating cash flowreport ↗
2021-FY—$25M$5.6M+ $0 short-term inv.$8.1M-$11M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 19 purchases ($6.5M), 0 sales ($0). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-10-21ADAR1 Capital Management, LLC; Schneeberger Daniel · 10% owner; 10% ownerOpen-market purchase331,979$1.66$551KForm 4
2026-10-20ADAR1 Capital Management, LLC; Schneeberger Daniel · 10% owner; 10% ownerOpen-market purchase254,342$1.60$406KForm 4
2026-10-19ADAR1 Capital Management, LLC; Schneeberger Daniel · 10% owner; 10% ownerOpen-market purchase336,528$1.51$507KForm 4
2026-09-16Doogan Declan · directorOpen-market purchase53,000$1.92$102KForm 4
2026-09-15Giordano Christopher Thomas · director, CEOOpen-market purchase4,850$1.82$9KForm 4
2026-09-11STAAB THOMAS R II · Chief Financial OfficerOpen-market purchase5,675$1.94$11KForm 4
2026-09-11Giordano Christopher Thomas · director, CEOOpen-market purchase6,000$1.88$11KForm 4
2026-09-03ADAR1 Capital Management, LLC; Schneeberger Daniel · 10% owner; 10% ownerOpen-market purchase900,000$1.78$1.6MForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 80 reporting institutions held 21.7M shares ($298.0M, 47.6% of shares outstanding).

#InstitutionSharesValue
1JANUS HENDERSON GROUP PLC1,815,474$29.1M
2Venrock Adviser, LLC1,675,262$26.8M
3PERCEPTIVE ADVISORS LLC1,447,782$23.2M
4Ikarian Capital, LLC1,017,600$16.3M
5Stonepine Capital Management, LLC975,200$15.6M
6Logos Global Management LP625,000$10.0M
7MORGAN STANLEY596,564$9.5M
8Velan Capital Investment Management LP583,333$9.3M
9ADAGE CAPITAL PARTNERS GP, L.L.C.540,126$8.6M
10Point72 Asset Management, L.P.533,965$8.5M
11MILLENNIUM MANAGEMENT LLC533,889$8.5M
12ARMISTICE CAPITAL, LLC478,827$7.7M
13Avidity Partners Management LP481,868$6.9M
14Siren, L.L.C.427,141$6.8M
15TD Asset Management Inc399,184$6.4M